<DOC>
	<DOCNO>NCT00868309</DOCNO>
	<brief_summary>This phase II study prospective , randomize , open-label , multi-center study United States , involve patient 18 70 year age , compare Anavip ( Antivenin Crotalinae [ pit viper ] equine immune F ( ab ) 2 ; Instituto Bioclon , Mexico City , Mexico ) CroFab ( Protherics Inc. , Nashville , Tennessee ) , currently approve product treatment Crotalinae ( pit viper ) envenomation US . The study design evaluate hypothesis last correction snakebite induce thrombocytopenia hypofibrinogenemia possible follow correction F ( ab ) 2 antivenom , analyze detail relationship among platelet count , fibrinogen , venom level , antivenom level subject present thrombocytopenia follow crotaline viper envenomation . In study expect see fall platelet count follow Fab treatment , commensurate report past . We hypothesize follow F ( ab ) 2 treatment would slower drop post-treatment platelet count , relatively high platelet count give point follow-up period . We hypothesize initial rise later fall platelet count would correspond rise fall antivenom level , would mirror concurrent drop rise level unbound circulate venom .</brief_summary>
	<brief_title>A Comparison Crotalinae Equine Immune F ( ab ) 2 Antivenom ( Anavip ) Crotalidae Polyvalent Immune Fab ,</brief_title>
	<detailed_description>The overall objective Phase 2 open-label comparative study demonstrate F ( ab ) 2 antivenom Anavip significantly longer plasma persistence Fab , associate slow rise venom level slow decline platelet count fibrinogen follow hospital discharge envenomated subject . The effectiveness F ( ab ) 2 prevent recurrence coagulopathies subject 's discharge hospital indicate , inherently , F ( ab ) 2 antivenom improve safety profile relative Fab antivenom CroFab treat envenomation crotaline viper . Each subject assess quantitative serum venom level . Relatively historical data exist support use venom level surrogate endpoint envenomation . However , change venom level correlate coagulopathic effect , acute phase venom toxicity post treatment period recurrent venom effect . Validation surrogate endpoint via correlation venom effect platelet count fibrinogen level phase II study intend support future study . The secondary endpoint determination coagulation abnormality follow period .</detailed_description>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Snake Bites</mesh_term>
	<mesh_term>Antivenins</mesh_term>
	<criteria>men woman 18 70 year age present emergency treatment pit viper bite inform consent document read sign subject allergy horse serum , sheep serum , papaya current use antivenom , use within last month current participation clinical drug study , participation within last month pregnancy breastfeed underlying medical condition significantly alter blood coagulation : thrombocytopenia , hemophilia , familial dysfibrinogenemia , leukemia , recent ingestion superwarfarin compound ( rat poison ) use medication expect affect platelet count , coagulation factor , fibrinogen : chemotherapeutic agent , warfarin , heparin , aspirin No clinical indication snake bite envenomation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Snake Bite</keyword>
	<keyword>Venom antivenom kinetics</keyword>
</DOC>